We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

63 hedge funds and large institutions have $52.9M invested in Adamas Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more capital invested

Capital invested by funds: $33.5M → $52.9M (+$19.4M)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

3% more funds holding

Funds holding: 61 → 63 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

52% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 25

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
12
Reduced
25
Closed
11
Calls
$141K
Puts
–
Net Calls
+$141K
Net Calls Change
+$104K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$2.04M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.59M
3
EIM
Essex Investment Management
Massachusetts
+$1.27M
4
Two Sigma Investments
Two Sigma Investments
New York
+$538K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$396K

Top Sellers

Rank Fund Capital Flow
1
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$1.22M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$1.08M
3
N
Nuveen
North Carolina
-$945K
4
BOS
Bingham Osborn & Scarborough
California
-$533K
5
Jane Street
Jane Street
New York
-$445K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$262K -$79.7K -20,600 -24%
Fisher Asset Management
27
Fisher Asset Management
Washington
$243K +$104 +27 +0%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$227K +$160K +41,308 +295%
Goldman Sachs
29
Goldman Sachs
New York
$223K -$190K -49,044 -48%
SFI
30
Susquehanna Fundamental Investments
Pennsylvania
$209K +$197K +50,840 New
EGM
31
Engineers Gate Manager
New York
$169K +$158K +40,947 New
JP Morgan Chase
32
JP Morgan Chase
New York
$166K -$301K -77,719 -66%
Deutsche Bank
33
Deutsche Bank
Germany
$157K +$69.4K +17,935 +88%
BOS
34
Bingham Osborn & Scarborough
California
$142K -$533K -137,686 -80%
SG Americas Securities
35
SG Americas Securities
New York
$141K -$3.87K -1,000 -3%
DA
36
DCF Advisers
Connecticut
$129K – – –
PP
37
PDT Partners
New York
$129K +$122K +31,425 New
Wells Fargo
38
Wells Fargo
California
$126K -$5.16K -1,333 -4%
VF
39
Virtu Financial
New York
$102K +$95.3K +24,641 New
Citadel Advisors
40
Citadel Advisors
Florida
$96K +$89.9K +23,241 New
Jane Street
41
Jane Street
New York
$92K -$445K -115,066 -84%
CHAM
42
Clear Harbor Asset Management
Connecticut
$86.7K +$81.4K +21,044 New
Creative Planning
43
Creative Planning
Kansas
$82K – – –
MFS
44
Mirabella Financial Services
United Kingdom
$77K +$72.1K +18,628 New
Charles Schwab
45
Charles Schwab
California
$74K +$69.1K +17,873 New
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$68K +$12.3K +3,176 +24%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$66K – – –
PNC Financial Services Group
48
PNC Financial Services Group
Pennsylvania
$62K – – –
State Street
49
State Street
Massachusetts
$60K -$137K -35,300 -71%
Qube Research & Technologies (QRT)
50
Qube Research & Technologies (QRT)
United Kingdom
$57K -$41.8K -10,812 -44%
1
2
3

ADMS Hedge Fund Activity: Q3 2020 in Review

63 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2020, worth a combined $52.9M — up 58% from $33.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ADMS positions and 11 closed out — a net gain of 2 holders — while 12 added to existing stakes and 25 trimmed.

The largest buyer was Opaleye Management, adding an estimated $2.04M. The largest seller was Emerald Mutual Fund Advisers Trust, cutting an estimated $1.22M.

  • 63 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2020, up from 61 in Q2 2020.
  • Funds reported $52.9M of Adamas Pharmaceuticals stock for Q3 2020, up 58% quarter-over-quarter.
  • 13 funds opened new Adamas Pharmaceuticals positions in Q3 2020 and 11 closed out, a net change of +2 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2020 was Opaleye Management, an estimated $2.04M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2020 was Emerald Mutual Fund Advisers Trust, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2020.